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Abstract
Background: The vinka-alkaloyd vinorelbine is a potentially valuable treatment in patients with HER2-
positive, trastuzumab-resistant advanced breast cancer. We sought to document the clinical activity of
vinorelbine-based salvage treatments in this clinical setting.
Methods: We analyzed a cohort of 424 consecutive women receiving trastuzumab-based therapy for
HER2-positive advanced breast cancer. Of these, 299 were identified as progressing during the initial
trastuzumab-based treatment, and 77 received vinorelbine-based therapy as first salvage treatment.
Central review of pathological specimens revealed that 70 patients had HER2-amplification detected by
FISH. For these patients we determined overall response rate (ORR = complete-CR + partial-PR) and
clinical benefit (CB = CR+PR+ Stable disease lasting at least 6 months), time to progression (TTP) and
overall survival (OS) from the initiation of vinorelbine-based salvage therapy.
Results: In 60 patients who were evaluable for tumor response, ORR and CB rates were 28% (95% C.I.
18%-41%) and 50% (95% C.I. 38%-62%), respectively. Median follow-up from the initiation of salvage
therapy was 15 months (range 1–63 months). Median TTP and OS were 7.1 months (95% C.I. 6.6–7.7
months) and 21 months (95% C.I. 14.3–27.7 months), respectively. No differences in clinical outcomes
were observed according to whether vinorelbine was administered as a single agent or in combination with
other cytostatics, or whether trastuzumab was stopped or continued beyond disease progression.
Conclusion: our findings suggests that vinorelbine-based combinations are active and should be further
evaluated in studies conducted in trastuzumab-resistant patients, including those evaluating newer HER2-
targeting agents.
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Trastuzumab is a monoclonal antibody directed against
the product of the HER2/neu oncogene, which is ampli-
fied in about 20–25% of breast cancer cases.[1] The com-
bination of trastuzumab and chemotherapy resulted in
improved clinical outcomes, compared with chemother-
apy, alone, in patients with HER2-positive advanced
breast cancer.[2,3] Because of unacceptable rates of car-
diac toxicity when trastuzumab was given in combination
with anthracycline-based therapy,[2] this monoclonal
antibody was registered for the treatment of HER2-posi-
tive advanced breast cancer patients with the taxanes pacl-
itaxel and docetaxel. Furthermore, several phase II trials
have been conducted using alternative regimens, which
were based on preclinical observations suggesting additiv-
ity or even synergism between trastuzumab and other
commonly used cytostatic agents. [4,5] One of these com-
pounds is vinorelbine, a vinka-alkaloyd derivative that
has shown remarkable clinical activity in anthracycline-
pre-treated advanced breast cancer patients.[6,7] This
drug is available both as intravenous and oral formula-
tions.[8] Preclinical synergism between vinorelbine and
trastuzumab was partially confirmed in the clinic in the
context of phase II trials, where up to 84% response rates
were reported when vinorelbine and trastuzumab were
used as first-line treatment in appropriately selected
advanced breast cancer patients. [9-12] Due to its intrinsic
antitumor activity and positive interaction with trastuzu-
mab, vinorelbine is a suitable salvage choice in HER2-pos-
itive advanced breast cancer patients whose disease has
progressed during an initial trastuzumab-based regimen.
Before the availability of the dual epidermal growth factor
receptor (EGFR) and HER2 tyrosine kinase inhibitor lap-
atinib,[13,14] treatment options in trastuzumab-resistant
patients included salvage chemotherapy with or without
the continuation of trastuzumab. [15-18] A recently pub-
lished randomized phase III trial with lapatinib and
capecitabine confirms that HER2 is still an exploitable tar-
get after trastuzumab-failure, opening the way to newer
treatment options in this setting.[13]
With the current retrospective analysis, we sought to
describe patterns of use and clinical activity of vinorel-
bine-based salvage therapy in trastuzumab-resistant
patients using data collected before the availability of lap-
atinib. In the absence of data from prospective trials, our
aim is to evaluate the potential worth of vinorelbine as a
component of salvage strategies including newer HER2-
targeting agents in trastuzumab-resistant patients.
Methods
Patients
Patients for this analysis were selected from a database
including 424 consecutive women with HER2 positive
advanced breast cancer who received trastuzumab-based
therapy for the treatment of advanced disease between
September 1999 and April 2007 at 11 different Institu-
tions in Italy, United Kingdom and Hungary (see
acknowledgments). No patients had previously received
trastuzumab as part of adjuvant treatment for operable
disease. For patients developing tumor progression during
the initial trastuzumab-based regimen, investigators at
each site were asked to provide details of the first post-pro-
gression treatment (drugs and doses, best tumor response,
date of further progression, and date of death or of last fol-
low-up visit). This study was not prospectively planned.
Thus, salvage treatments were indicated by treating physi-
cians at each Institution. Follow-up information was
updated as of December 2007.
Being a retrospective analysis based on patients treated
according to standards of care, no specific informed con-
sent was obtained. However, data collection and provi-
sion was conducted in compliance with the ethical
requirements of each of the participating Institutions.
Statistical methods
Tumor response was recorded by treating physicians at
each site according to the World Health Organization cri-
teria.[19] Response rate was defined as the proportion of
patients achieving complete or partial remission
(CR+PR). Imaging studies were not available to centrally
reassess response rates. Patients with disease that was con-
fined to the bone or who had effusions as the only evi-
dence of metastatic disease were considered non
evaluable for response, as were patients with isolated cen-
tral-nervous disease progression. For all patients time-to
progression (TTP) and overall survival (OS) were calcu-
lated by the Kaplan Meyer method starting from the date
of salvage therapy start.
Comparisons between categorical variables evaluated by
the Chi Square or the Fisher's exact test. Survival curves
were compared by the log-rank test. Statistical significance
was set at p < 0.05. All the analyses were conducted by the
SPSS 15.0 statistical package
Results
We identified a total of 299 patients progressing during
the initial trastuzumab-based treatment. Of these
patients, 77 received vinorelbine-based therapy as first sal-
vage treatment. We excluded 7 patients because their
HER2 status was either 2+ without further evaluation of
HER2 amplification, or because HER2 positivity had been
defined by unconventional methods (i.e. percentage of
positive cells) and tissue blocks were unavailable for reas-
sessment. For the remaining 70 patients, central assess-
ment by fluorescence in situ hybridization (FISH)
confirmed HER2/neu amplification in their tumor mate-
rial.Page 2 of 9
(page number not for citation purposes)
BMC Cancer 2008, 8:209 http://www.biomedcentral.com/1471-2407/8/209Patients selected for the analysis had previously received
trastuzumab combined with weekly (2) or three-weekly
(31) docetaxel, weekly (12) or three-weekly (5) paclitaxel,
three-weekly docetaxel plus epirubicin (4), weekly
docetaxel plus carboplatin (2), capecitabine (1), infu-
sional 5-fluorouracil (1), vinorelbine plus infusional 5-
fluorouracil (1), and vinorelbine alone (4). These latter 5
patients had stopped vinorelbine-based therapy before
disease progression either because of complete tumor
response (1 patient), long-lasting stable disease which
was maintained with trastuzumab alone (3 patients), or
toxicity determining treatment discontinuation (1
patient). Additionally, 4 patients had received trastuzu-
mab alone, whereas for 3 patients the initial trastuzumab-
containing regimen was not known.
Response rate (CR+PR) to the initial trastuzumab-con-
taining regimen was 55% in 69 evaluable patients.
Median tumor progression during the initial trastuzumab-
containing regimen was 8.6 months (95% C.I. 7.5 to 9.6
months).
Patient characteristics before the initiation of vinorelbine-
based salvage treatment are summarized in Table 1. Nota-
bly, most of the patients had visceral involvement and a
substantial proportion had metastatic central nervous sys-
tem involvement. Vinorelbine-based salvage treatments
are summarized in Table 2. Trastuzumab was continued
beyond disease progression in 36 patients (51%) and
stopped in the remaining 34 patients (49%). In 60 evalu-
able patients, the overall response rate was 28% (95% C.I.
18%-41%) (Table 3). Additionally, 13 patients experi-
enced disease stabilization that lasted 6 months or longer,
for a clinical benefit rate of 50% (95% C.I. 38%-62%).
Response and clinical benefit rates did not differ signifi-
cantly according to whether patients received single agent
vinorelbine or vinorelbine combined with other agents,
or whether trastuzumab was continued or not beyond dis-
ease progression. Of the 5 patients who were re-treated
Table 1: Patient characteristics (n 70)1
Variable Values (%)2
Median Age in years (range) 55 (32–77)
Stage at Initial Diagnosis of Breast Cancer
I/II 41 (59)
III 17 (24)
IV 12 (17)
Hormone Receptor Status
ER and or PgR positive 33 (47)
ER and PgR Negative 35 (50)
ER and PgR Unknown 2 (3)
Exposure to anthracycline before the initial T-based regimen3 46 (66)
Exposure to taxane before the initial T-based regimen3 18 (26)
Prior Lines of Chemotherapy for Metastatic Disease4
1 48 (68)
2 10 (14)
≥ 3 12 (17)
Initial Trastuzumab-based regimen
Docetaxel 75–100 mg/m2 q3wks + T 31 (44)
Paclitaxel 80–90 mg/m2 weekly +T 12 (17)
Paclitaxel 175 mg/m2 q3wks + T 5 (7)
Vinorelbine 25–30 mg/m2 weekly + T 4 (6)
Docetaxel 75 mg/m2 + Epi-doxorubicin 75 mg/m2 q3wks + T 4 (6)
T alone 4 (6)
Other regimens 7 (10)
Unknown 3 (4)
Median Number of Metastatic Sites 2 (1–6)
Pattern of Metastatic Disease
Visceral (Liver + Lung) 57 (81)
Non Visceral/Non CNS (Bone, Soft Tissue, Effusions) 11 (16)
Central Nervous System (plus other sites) 17 (24)
T, Trastuzumab; CNS, central nervous system.
1All patients had HER2 amplification confirmed by central reassessment of tumor material by fluorescence in situ hybridization
2Because of rounding, the sum of percentages does not always equal 100.
3Exposure to these drugs in the neoadjuvant, adjuvant or metastatic setting before the initial trastuzumab-based regimen.
4Including the initial trastuzumab-based regimenPage 3 of 9
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response, two achieved a stable disease lasting 6.1 and 3.2
months, and two had disease progression. Of the 39 eval-
uable patients who underwent monochemotherapy with
vinorelbine, 13 received chemotherapy alone and 26 con-
tinued trastuzumab beyond progression with vinorelbine.
ORR was 38% (95% C.I 18%-64%) and 15% (95% C.I.
6%-34%) according to whether trastuzumab was stopped
or continued, respectively, but this difference was not sta-
tistically significant (two-tailed Fisher's exact test, p =
0.13). Due to the small number of patients involved,
these groups were not submitted to further analysis of
clinical outcomes.
At a median follow-up measured from the initiation of
salvage treatment of 15 months (range 1–63 months), 60
patients had progressed and 46 had died because of tumor
progression. Median TTP and OS measured from the ini-
tiation of salvage treatment were 7.1 months (95% C.I.
6.6–7.7 months) and 21 months (95% C.I. 14.3–27.7
months), respectively (Figure 1a and 1b). Time-to pro-
gression did not differ substantially according to whether
patients received single-agent vinorelbine, or vinorelbine
combined with other cytostatics (Figure 2a), or whether
trastuzumab was continued or stopped (Figure 2b). The
17 patients with central nervous system involvement were
managed with radiation therapy (either whole brain, ster-
eotactic irradiation or both) as part of multimodal treat-
ment. All these patients except one had had central
nervous system progression during the initial trastuzu-
mab-based therapy. Interestingly, their time-to progres-
sion and overall survival measured from the initiation of
salvage with vinroelbine-based therapy did not differ sub-
stantially from that of patients without central nervous
system involvement (Figure 3a and 3b).
Discussion
Our retrospective analysis shows that vinorelbine-based
therapy is a valuable salvage option for patients with
advanced HER2-posive (HER2/neu amplification) whose
disease has progressed during an initial trastuzumab-
based regimen. A clinical benefit rate of 50% and a
median time-to progression of about 7 months are note-
worthy, considering that a high proportion of these
patients had visceral involvement and about a quarter had
central nervous system metastases. Having been generated
from a retrospective analysis, our results should be evalu-
ated with caution because of the well known biases con-
cerned with this methodology. For example, tumor
response was recorded by each investigator at each site
and no centralized review was performed. Furthermore, in
the estimation of time-to progression, it must be consid-
ered that timing of disease assessment was not pre-
planned and uniform between institutions. However, we
believe that our findings represent a reasonable estima-
tion of the clinical activity of vinorelbine-based salvage
regimens in the daily clinical practice. Cross-comparisons
of data generated from retrospective analyses with that of
prospective studies are not appropriate in general, but
may serve to evaluate the plausibility of our findings. Cur-
rently, only two prospective, randomized trials have pro-
vided data on the treatment of patients with trastuzumab-
resistant disease. One is the already mentioned study with
Table 2: Vinorelbine-based salvage treatments
Type Number %*
Vinorelbine alone 16 23
Vinorelbine + T 32 46
Vinorelbine + Infusional 5-FU or Capecitabine 8 11
Vinorelbine + Infusional 5-FU or Capecitabine + T 3 4
Vinorelbine + Gemcitabine 8 11
Vinorelbine + other agents** 3 4
Legend: T, trastuzumab
*Because of rounding sum of percentages does not equal 0.
**1 patients in this group received also trastuzumab
Table 3: Summary of response rates to vinorelbine-based salvage treatments
Response Overall Single agent vinorelbine Vinorelbine + other 
chemotherapies
Continuing trastuzumab Stopping Trastuzumab
N60 N 391 N 21 N 29 N 31
ORR 17 (28%) 9 (23%) 8 (38%)2 6 (21%) 11 (36%)3
CR 1 (2%) 0 (0%) 1 (5%) 0 (0%) 1 (3%)
PR 16 (27%) 9 (23%) 7 (33%) 6 (21%) 10 (32%)
SD 16 (27%) 12 (31%) 4 (19%) 8 (28%) 8 (26%)
PD 27 (45%) 18 (46%) 9 (43%) 15 (52%) 12 (39%)
CB (CR+PR+SD ≥ 6 
months)
30 (50%) 15 (38%) 11 (52%) 13 (48%) 18 (58%)
ORR; overall response rate (CR+ PR); CR, complete remission: PR, partial response; SD, stable disease; PD, progressive disease; CB, clinical benefit
126 of these patients received single-agent chemotherapy with vinorelbine and continued trastuzumab beyond progression
2Two tailed Fisher's Exact test for the difference in ORR (CR+PR) = 0.24
3 Two tailed Fisher's Exact test for the difference in ORR (CR+PR) = 0.26Page 4 of 9
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Kaplan-Meyer estimates of time-to progression (a) and overall survival (b) for 70 patients selected for the analysisFigure 1
Kaplan-Meyer estimates of time-to progression (a) and overall survival (b) for 70 patients selected for the anal-
ysis.
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a. Kaplan-Meyer estimates of time-to progression according whether vinorelbine was given alone (solid line) or combined with other agents (dashed lin )Figu e 2
a. Kaplan-Meyer estimates of time-to progression according whether vinorelbine was given alone (solid line) 
or combined with other agents (dashed line). Median time-to progression was 7.2 and 6.1 months for patients receiving 
single agent vinorelbine or vinorelbine with other chemotherapy agents (log-rank test, p = 0.76). b. Kaplan-Meyer estimates of 
time-to progression according whether trastuzumab was stopped (solid line) or continued (dashed line) during salvage treat-
ment with vinorelbine. Median time-to progression was 7.1 and 6.1 months for patients stopping or continuing trastuzumab, 
respectively (log-rank test, p = 0.10).
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Kaplan-Meyer estimates of time-to progression (a) and overall survival (b) for patients with (solid line) or without (dashed line) central nervous system me astasesFigure 3
Kaplan-Meyer estimates of time-to progression (a) and overall survival (b) for patients with (solid line) or with-
out (dashed line) central nervous system metastases. Median time to progression was 7.1 and 6.7 months for patients 
with and without central nervous system involvement, respectively (long-rank test, p = 0.51). Median overall survival was 16.4 
and 22.9 months for patients with and without central nervous system involvement, respectively (log-rank test, p = 0.24)
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conducted in anthracycline and taxane pre-treated HER2-
positive advance breast cancer patients whose disease was
clinically resistant to trastuzumab, was closed after the
first interim analysis reporting an about 50% reduction in
the risk of relapse for patients receiving lapatinib plus
capecitabine, compared with capecitabine alone. This
translated in an about 4 months improvement in median
time-to progression (from 4.4 to 8.4 months).
Response rate was 14% with capecitabine alone and 22%
with the addition of lapatinib to capecitabine. As a result
of this trial, lapatinib plus capecitabine is now an accepted
option for trastuzumab resistant patients.[20]
Another study sought to evaluate the worth of continuing
trastuzumab beyond disease progression in combination
with capecitabine, compared with capecitabine alone in
patients who had failed first-line trastuzumab-based ther-
apy.[21] This study was a valuable attempt at settling the
ongoing controversy of the worth of continuing trastuzu-
mab when disease progresses during an initial trastuzu-
mab-based treatment. Unfortunately, due to slow accrual,
the study was closed prematurely when it had randomized
only 156 of the 482 planned patients. In this small cohort,
response rate was 24.6% and 49.1% in patients who
stopped and continued trastuzumab, respectively. Con-
tinuation of trastuzumab was also associated with a 30%
reduction in the risk of tumor progression, translating in
an about 3-month increase in median time to progres-
sion, from 5.6 to 8.5 months. Our findings provide a sug-
gestion that vinorelbine-based salvage therapy is
associated with a median time to progression that might
be close to that of the experimental arms of these two ran-
domized trial. On account of these results, vinorelbine-
based therapy should be evaluated in studies conducted
in trastuzumab-resistant patients, including those evaluat-
ing newer HER2-targeting agents.
Another limitation to the applicability of these results is
the fact that a substantial number of HER2-positive
advanced breast cancer patient receive vinorelbine as part
of the first-line trastuzumab-based therapy in the clinical
practice. In a previous comprehensive analysis of our
database, we observed that this option was pursued in
about 38% of patients, compared with 56% receiving a
taxane + trastuzumab (Montemurro et al, in press).
Although data leading to the registration of trastuzumab
were originated from prospective randomized studies
with taxanes,[2,3] vinorelbine and trastuzumab-based
regimens have become popular because of high efficacy
documented in phase II trials and a favorable toxicity pro-
file. This, apart from treating physicians' preferences
towards salvage regimens, partly explain the reason why
only 26% of patients that we identified as progressing dur-
ing an initial trastuzumab-based regimen received vinore-
lbine-based salvage therapy. It must be noted, however,
that due to the increasing use of taxanes and trastuzumab
in the adjuvant setting, vinorelbine qualifies as a valuable
option in recurring patients, whose disease fulfils the cri-
teria of trastuzumab resistance.
Finally we could not find significant differences in clinical
outcomes between vinorelbine-based strategies (i.e. con-
tinuing or stopping trastuzumab beyond disease progres-
sion or adding another agent to vinorelbine).
Conclusion
Our analysis suggests that vinorelbine-based therapy has
encouraging clinical activity in patients with trastuzumab-
resistant HER2-positive breast cancer and might represent
a platform for future developments in this clinical setting.
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